Volitionrx limited announces full fiscal year 2022 financial results and business update

Conference call to discuss financial and operational results scheduled for thursday, march 16, at 8:30 a.m. u.s. eastern time executed global licensing and supply agreement with heska corporation ("heska") to distribute nu.q® vet cancer test at the point of care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones.
VNRX Ratings Summary
VNRX Quant Ranking